Candidates

Every idea we’re putting to the test.

Each candidate is a real drug against a real target in the cancer dogs and people share. The engine tries to disprove each one with a pre-registered kill-test — and keeps only what survives. Open any idea to see its evidence and the run that tested it.

Ipatasertib → AKT1 (PI3Kα→AKT1 axis node) SURVIVED
target AKT1 · still standing
Capivasertib → AKT1 (PI3Kα→AKT1 axis node) SURVIVED
target AKT1 · still standing
Copanlisib warhead → canine PIK3CA (PROTAC warhead) SURVIVED
target PIK3CA_CANINE · still standing
Taselisib → canine PIK3CA (degrader engagement) SURVIVED
target PIK3CA_CANINE · still standing
Inavolisib → canine PIK3CA (degrader engagement) SURVIVED
target PIK3CA_CANINE · still standing
STX-478 (mutant-selective allosteric PI3Ka) × PIK3CA SURVIVED
target PIK3CA · still standing
ZSTK474 (PI3K-PROTAC warhead) × PIK3CA SURVIVED
target PIK3CA · still standing
genistein × PIK3CA SURVIVED
target PIK3CA · still standing
sorafenib × VEGFR2 SURVIVED
target KDR · still standing
cediranib × VEGFR2 SURVIVED
target KDR · still standing
motesanib × VEGFR2 SURVIVED
target KDR · still standing
tivozanib × VEGFR2 SURVIVED
target KDR · still standing
vandetanib × VEGFR2 SURVIVED
target KDR · still standing
nintedanib × VEGFR2 SURVIVED
target KDR · still standing
dactolisib × PIK3CA SURVIVED
target PIK3CA · still standing
lenvatinib × VEGFR2 SURVIVED
target KDR · still standing
cabozantinib × VEGFR2 SURVIVED
target KDR · still standing
serabelisib × PIK3CA SURVIVED
target PIK3CA · still standing
gedatolisib × PIK3CA SURVIVED
target PIK3CA · still standing
duvelisib × PIK3CA SURVIVED
target PIK3CA · still standing
copanlisib × PIK3CA SURVIVED
target PIK3CA · still standing
taselisib × PIK3CA SURVIVED
target PIK3CA · still standing
pictilisib × PIK3CA SURVIVED
target PIK3CA · still standing
inavolisib × PIK3CA SURVIVED
target PIK3CA · still standing
sunitinib × VEGFR2 SURVIVED
target KDR · still standing
pazopanib × VEGFR2 SURVIVED
target KDR · still standing
axitinib × VEGFR2 SURVIVED
target KDR · still standing
regorafenib × VEGFR2 SURVIVED
target KDR · still standing
Toceranib (VEGFR2/KDR inhibitor) for angiogenesis-driven hemangiosarcoma SURVIVED
target KDR · still standing
Alpelisib (PI3Ka inhibitor) for PIK3CA-driven hemangiosarcoma SURVIVED
target PIK3CA · still standing
mebendazole × VEGFR2 SURVIVED
target KDR · still standing
RLY-2608 (mutant-selective allosteric PI3Ka) × PIK3CA RUNNING
target PIK3CA · needs more testing
CNX-1351 (covalent PI3Ka, Cys862) × PIK3CA RUNNING
target PIK3CA · needs more testing
PRN1371 (covalent kinase tool, VEGFR2 engagement) × KDR RUNNING
target KDR · needs more testing
Is the PIK3CA-mutant HSA subset immunosuppressed? (TME deconvolution crux) RUNNING
target PIK3CA · needs more testing
carvedilol × VEGFR2 KILLED
target KDR · ruled out
losartan × VEGFR2 KILLED
target KDR · ruled out
nelfinavir × VEGFR2 KILLED
target KDR · ruled out
nelfinavir × PIK3CA KILLED
target PIK3CA · ruled out
perphenazine × PIK3CA KILLED
target PIK3CA · ruled out
trifluoperazine × PIK3CA KILLED
target PIK3CA · ruled out
honokiol × PIK3CA KILLED
target PIK3CA · ruled out
valproic-acid × PIK3CA KILLED
target PIK3CA · ruled out
sulforaphane × PIK3CA KILLED
target PIK3CA · ruled out
propranolol × VEGFR2 KILLED
target KDR · ruled out
fenofibrate × VEGFR2 KILLED
target KDR · ruled out